MITOTIC-ACTIVITY, APOPTOSIS AND TRPM-2 MESSENGER-RNA EXPRESSION IN DMBA-INDUCED RAT MAMMARY-CARCINOMA TREATED WITH ANTIESTROGEN TOREMIFENE

被引:55
作者
HUOVINEN, R
WARRI, A
COLLAN, Y
机构
[1] UNIV TURKU,CENT HOSP,DEPT ONCOL & RADIOTHERAPY,SF-20520 TURKU 52,FINLAND
[2] ORION CORP FARMOS,CANC RES LAB,SF-20101 TURKU,FINLAND
[3] UNIV TURKU,DEPT PATHOL,SF-20520 TURKU 52,FINLAND
关键词
D O I
10.1002/ijc.2910550429
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anti-estrogen toremifene inhibits growth of the 7,12-dimethylbenz(a)anthracene(DMBA)-induced rat mammary carcinoma. The changes in proliferation and cell death were studied in detail. Proliferation was measured by counting mitotic figures in histologic sections, expressed by volume-corrected mitotic index (M/V INDEX). Respective volume corrected apoptotic index (A/V INDEX) was measured by counting apoptotic nuclei in the same sections. The presence of apoptotic cells was confirmed by transmission electron microscopy. In the untreated tumors, both mitosis and apoptosis were frequent. In the toremifene-treated tumors, the mean M/V INDEX was about half of the mean M/V INDEX in the untreated control tumors. The mean A/V INDEX in the toremifene-treated tumors was about 3/4 of the mean A/V INDEX in the controls. In toremifene-treated tumors, A/V INDEX was strongly correlated with TRPM-2-gene expression, which was also enhanced when compared with the controls. TRPM-2 gene has been associated with programmed cell death induced by hormonal ablation in prostate- and breast-cancer cells. No such correlation was seen in control tumors. These findings suggest that, in the DMBA-tumor model, toremifene affects the cell turnover by inhibiting mitotic activity and modifying abundant spontaneous apoptosis. In this model, the inhibition of tumor growth results mostly from reduction of mitotic activity. (C) 1993 Wiley-Liss, Inc.
引用
收藏
页码:685 / 691
页数:7
相关论文
共 35 条
[21]   ANTITUMOR-ACTIVITY OF FOLLIGEN, A NOVEL GONADOTROPIN-RELEASING-HORMONE ANALOG AGAINST DMBA-INDUCED TUMORS IN THE RAT [J].
NICHOLSON, RI ;
KERI, G .
TUMOR BIOLOGY, 1992, 13 (1-2) :44-50
[22]   FLOW CYTOMETRIC ANALYSIS OF ESTROGEN-RECEPTORS IN RELATION TO HISTOPATHOLOGIC CHARACTERISTICS OF DMBA-INDUCED MAMMARY-TUMORS IN RATS [J].
PENA, L ;
FLORES, JM ;
GONZALEZ, M ;
PIZARRO, M ;
GOMEZ, M .
EXPERIMENTAL PATHOLOGY, 1991, 43 (3-4) :221-228
[23]   NEW EVIDENCE CONCERNING MOLECULAR BASIS OF RESTORATIVE EFFECT OF DNA IN CULTURED MAMMALIAN CELLS [J].
PETROVIC, D ;
FERLEVID.A ;
HABAZIN, V ;
VUKOVIC, B .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY AND RELATED STUDIES IN PHYSICS CHEMISTRY AND MEDICINE, 1970, 18 (03) :243-+
[24]   ANTITUMOR ACTIONS OF TOREMIFENE IN THE 7,12-DIMETHYLBENZANTHRACENE (DMBA)-INDUCED RAT MAMMARY-TUMOR MODEL [J].
ROBINSON, SP ;
MAUEL, DA ;
JORDAN, VC .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (12) :1817-1821
[25]  
Sambrook J., 1989, MOL CLONING LAB MANU
[26]   PROPORTIONS OF MITOTIC AND APOPTOTIC CELLS IN A RANGE OF UNTREATED EXPERIMENTAL-TUMORS [J].
SARRAF, CE ;
BOWEN, ID .
CELL AND TISSUE KINETICS, 1988, 21 (01) :45-49
[27]   ACTIVE CELL-DEATH IN HORMONE-DEPENDENT TISSUES [J].
TENNISWOOD, MP ;
GUENETTE, RS ;
LAKINS, J ;
MOOIBROEK, M ;
WONG, P ;
WELSH, JE .
CANCER AND METASTASIS REVIEWS, 1992, 11 (02) :197-220
[28]   TOREMIFENE, A NEW ANTIESTROGENIC COMPOUND, FOR TREATMENT OF ADVANCED BREAST-CANCER - PHASE-II STUDY [J].
VALAVAARA, R ;
PYRHONEN, S ;
HEIKKINEN, M ;
RISSANEN, P ;
BLANCO, G ;
THOLIX, E ;
NORDMAN, E ;
TASKINEN, P ;
HOLSTI, L ;
HAJBA, A .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (04) :785-790
[29]   MULTICENTER PHASE-II EFFICACY TRIAL OF TOREMIFENE IN TAMOXIFEN-REFRACTORY PATIENTS WITH ADVANCED BREAST-CANCER [J].
VOGEL, CL ;
SHEMANO, I ;
SCHOENFELDER, J ;
GAMS, RA ;
GREEN, MR .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :345-350
[30]  
Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18